JP7292567B2 - 局所日焼け止め製剤 - Google Patents
局所日焼け止め製剤 Download PDFInfo
- Publication number
- JP7292567B2 JP7292567B2 JP2021514553A JP2021514553A JP7292567B2 JP 7292567 B2 JP7292567 B2 JP 7292567B2 JP 2021514553 A JP2021514553 A JP 2021514553A JP 2021514553 A JP2021514553 A JP 2021514553A JP 7292567 B2 JP7292567 B2 JP 7292567B2
- Authority
- JP
- Japan
- Prior art keywords
- wax
- sunscreen
- formulation according
- sunscreen formulation
- formulation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000203 mixture Substances 0.000 title claims description 143
- 238000009472 formulation Methods 0.000 title claims description 129
- 239000000516 sunscreening agent Substances 0.000 title claims description 89
- 230000000475 sunscreen effect Effects 0.000 title claims description 88
- 230000000699 topical effect Effects 0.000 title description 3
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 claims description 33
- 210000003491 skin Anatomy 0.000 claims description 28
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 claims description 27
- 150000001335 aliphatic alkanes Chemical class 0.000 claims description 26
- 229910044991 metal oxide Inorganic materials 0.000 claims description 19
- 150000004706 metal oxides Chemical class 0.000 claims description 19
- 239000002562 thickening agent Substances 0.000 claims description 18
- 239000001993 wax Substances 0.000 claims description 17
- 239000007787 solid Substances 0.000 claims description 16
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 claims description 16
- 239000004408 titanium dioxide Substances 0.000 claims description 14
- 239000011787 zinc oxide Substances 0.000 claims description 13
- 238000000034 method Methods 0.000 claims description 12
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 claims description 11
- 206010042496 Sunburn Diseases 0.000 claims description 10
- VYGQUTWHTHXGQB-FFHKNEKCSA-N Retinol Palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C VYGQUTWHTHXGQB-FFHKNEKCSA-N 0.000 claims description 8
- 239000004166 Lanolin Substances 0.000 claims description 7
- 235000019388 lanolin Nutrition 0.000 claims description 7
- 239000007788 liquid Substances 0.000 claims description 7
- 239000002245 particle Substances 0.000 claims description 7
- 230000005855 radiation Effects 0.000 claims description 7
- 150000003626 triacylglycerols Chemical class 0.000 claims description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 6
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 6
- 239000006184 cosolvent Substances 0.000 claims description 6
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 claims description 6
- 229940032094 squalane Drugs 0.000 claims description 6
- HLZKNKRTKFSKGZ-UHFFFAOYSA-N tetradecan-1-ol Chemical compound CCCCCCCCCCCCCCO HLZKNKRTKFSKGZ-UHFFFAOYSA-N 0.000 claims description 6
- MGSRCZKZVOBKFT-UHFFFAOYSA-N thymol Chemical compound CC(C)C1=CC=C(C)C=C1O MGSRCZKZVOBKFT-UHFFFAOYSA-N 0.000 claims description 6
- 208000000453 Skin Neoplasms Diseases 0.000 claims description 5
- 235000013871 bee wax Nutrition 0.000 claims description 5
- 239000012166 beeswax Substances 0.000 claims description 5
- 230000005779 cell damage Effects 0.000 claims description 5
- 208000037887 cell injury Diseases 0.000 claims description 5
- 229960000541 cetyl alcohol Drugs 0.000 claims description 5
- 239000000463 material Substances 0.000 claims description 5
- 239000002674 ointment Substances 0.000 claims description 5
- 239000012188 paraffin wax Substances 0.000 claims description 5
- 210000004927 skin cell Anatomy 0.000 claims description 5
- SNPLKNRPJHDVJA-ZETCQYMHSA-N D-panthenol Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCCO SNPLKNRPJHDVJA-ZETCQYMHSA-N 0.000 claims description 4
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 claims description 4
- 239000012164 animal wax Substances 0.000 claims description 4
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 4
- 239000003974 emollient agent Substances 0.000 claims description 4
- 229940039717 lanolin Drugs 0.000 claims description 4
- 239000012169 petroleum derived wax Substances 0.000 claims description 4
- 235000019172 retinyl palmitate Nutrition 0.000 claims description 4
- 229940108325 retinyl palmitate Drugs 0.000 claims description 4
- 239000011769 retinyl palmitate Substances 0.000 claims description 4
- 235000010384 tocopherol Nutrition 0.000 claims description 4
- 229960001295 tocopherol Drugs 0.000 claims description 4
- 229930003799 tocopherol Natural products 0.000 claims description 4
- 239000011732 tocopherol Substances 0.000 claims description 4
- 239000012178 vegetable wax Substances 0.000 claims description 4
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 claims description 4
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 claims description 3
- WCOXQTXVACYMLM-UHFFFAOYSA-N 2,3-bis(12-hydroxyoctadecanoyloxy)propyl 12-hydroxyoctadecanoate Chemical compound CCCCCCC(O)CCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCC(O)CCCCCC)COC(=O)CCCCCCCCCCC(O)CCCCCC WCOXQTXVACYMLM-UHFFFAOYSA-N 0.000 claims description 3
- 244000146553 Ceiba pentandra Species 0.000 claims description 3
- 235000003301 Ceiba pentandra Nutrition 0.000 claims description 3
- 240000000111 Saccharum officinarum Species 0.000 claims description 3
- 235000007201 Saccharum officinarum Nutrition 0.000 claims description 3
- 239000004163 Spermaceti wax Substances 0.000 claims description 3
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 claims description 3
- 239000005844 Thymol Substances 0.000 claims description 3
- 239000004204 candelilla wax Substances 0.000 claims description 3
- 235000013868 candelilla wax Nutrition 0.000 claims description 3
- 229940073532 candelilla wax Drugs 0.000 claims description 3
- 239000004203 carnauba wax Substances 0.000 claims description 3
- 235000013869 carnauba wax Nutrition 0.000 claims description 3
- 239000012185 ceresin wax Substances 0.000 claims description 3
- XXJWXESWEXIICW-UHFFFAOYSA-N diethylene glycol monoethyl ether Chemical compound CCOCCOCCO XXJWXESWEXIICW-UHFFFAOYSA-N 0.000 claims description 3
- 229940075557 diethylene glycol monoethyl ether Drugs 0.000 claims description 3
- IUJAMGNYPWYUPM-UHFFFAOYSA-N hentriacontane Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCC IUJAMGNYPWYUPM-UHFFFAOYSA-N 0.000 claims description 3
- 229940057917 medium chain triglycerides Drugs 0.000 claims description 3
- 239000002480 mineral oil Substances 0.000 claims description 3
- 239000012170 montan wax Substances 0.000 claims description 3
- KSCKTBJJRVPGKM-UHFFFAOYSA-N octan-1-olate;titanium(4+) Chemical compound [Ti+4].CCCCCCCC[O-].CCCCCCCC[O-].CCCCCCCC[O-].CCCCCCCC[O-] KSCKTBJJRVPGKM-UHFFFAOYSA-N 0.000 claims description 3
- 229940101267 panthenol Drugs 0.000 claims description 3
- 235000020957 pantothenol Nutrition 0.000 claims description 3
- 239000011619 pantothenol Substances 0.000 claims description 3
- 239000004170 rice bran wax Substances 0.000 claims description 3
- 235000019384 rice bran wax Nutrition 0.000 claims description 3
- 239000012176 shellac wax Substances 0.000 claims description 3
- 229920002545 silicone oil Polymers 0.000 claims description 3
- 201000000849 skin cancer Diseases 0.000 claims description 3
- 235000019385 spermaceti wax Nutrition 0.000 claims description 3
- 229940031439 squalene Drugs 0.000 claims description 3
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 claims description 3
- 239000010677 tea tree oil Substances 0.000 claims description 3
- 229940111630 tea tree oil Drugs 0.000 claims description 3
- 229960000790 thymol Drugs 0.000 claims description 3
- 235000015112 vegetable and seed oil Nutrition 0.000 claims description 3
- 239000008158 vegetable oil Substances 0.000 claims description 3
- 239000000341 volatile oil Substances 0.000 claims description 3
- SBASXUCJHJRPEV-UHFFFAOYSA-N 2-(2-methoxyethoxy)ethanol Chemical compound COCCOCCO SBASXUCJHJRPEV-UHFFFAOYSA-N 0.000 claims description 2
- LEACJMVNYZDSKR-UHFFFAOYSA-N 2-octyldodecan-1-ol Chemical compound CCCCCCCCCCC(CO)CCCCCCCC LEACJMVNYZDSKR-UHFFFAOYSA-N 0.000 claims description 2
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 claims description 2
- 240000007594 Oryza sativa Species 0.000 claims description 2
- 235000007164 Oryza sativa Nutrition 0.000 claims description 2
- BTFJIXJJCSYFAL-UHFFFAOYSA-N arachidyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCO BTFJIXJJCSYFAL-UHFFFAOYSA-N 0.000 claims description 2
- 239000012179 bayberry wax Substances 0.000 claims description 2
- 229940093499 ethyl acetate Drugs 0.000 claims description 2
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 claims description 2
- 229940093471 ethyl oleate Drugs 0.000 claims description 2
- 229940119170 jojoba wax Drugs 0.000 claims description 2
- 235000009566 rice Nutrition 0.000 claims description 2
- 239000004480 active ingredient Substances 0.000 description 11
- 239000004615 ingredient Substances 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 239000003921 oil Substances 0.000 description 6
- 235000019198 oils Nutrition 0.000 description 6
- 239000004215 Carbon black (E152) Substances 0.000 description 5
- 229930195733 hydrocarbon Natural products 0.000 description 5
- 150000002430 hydrocarbons Chemical class 0.000 description 5
- 206010015150 Erythema Diseases 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 239000002537 cosmetic Substances 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 230000037380 skin damage Effects 0.000 description 3
- 210000000434 stratum corneum Anatomy 0.000 description 3
- 206010004146 Basal cell carcinoma Diseases 0.000 description 2
- 208000009621 actinic keratosis Diseases 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 238000002845 discoloration Methods 0.000 description 2
- 231100000321 erythema Toxicity 0.000 description 2
- 150000002191 fatty alcohols Chemical class 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- 230000035515 penetration Effects 0.000 description 2
- 230000003711 photoprotective effect Effects 0.000 description 2
- 230000003449 preventive effect Effects 0.000 description 2
- 230000004224 protection Effects 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- MEZZCSHVIGVWFI-UHFFFAOYSA-N 2,2'-Dihydroxy-4-methoxybenzophenone Chemical compound OC1=CC(OC)=CC=C1C(=O)C1=CC=CC=C1O MEZZCSHVIGVWFI-UHFFFAOYSA-N 0.000 description 1
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
- -1 99%) Chemical compound 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 240000004355 Borago officinalis Species 0.000 description 1
- 235000007689 Borago officinalis Nutrition 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 244000020518 Carthamus tinctorius Species 0.000 description 1
- 235000003255 Carthamus tinctorius Nutrition 0.000 description 1
- 244000060011 Cocos nucifera Species 0.000 description 1
- 235000013162 Cocos nucifera Nutrition 0.000 description 1
- 235000004866 D-panthenol Nutrition 0.000 description 1
- 239000011703 D-panthenol Substances 0.000 description 1
- XMSXQFUHVRWGNA-UHFFFAOYSA-N Decamethylcyclopentasiloxane Chemical compound C[Si]1(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O1 XMSXQFUHVRWGNA-UHFFFAOYSA-N 0.000 description 1
- 244000020551 Helianthus annuus Species 0.000 description 1
- 235000003222 Helianthus annuus Nutrition 0.000 description 1
- 240000000950 Hippophae rhamnoides Species 0.000 description 1
- 235000003145 Hippophae rhamnoides Nutrition 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- 235000009134 Myrica cerifera Nutrition 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 240000007817 Olea europaea Species 0.000 description 1
- 244000025272 Persea americana Species 0.000 description 1
- 235000008673 Persea americana Nutrition 0.000 description 1
- 206010051246 Photodermatosis Diseases 0.000 description 1
- 206010039792 Seborrhoea Diseases 0.000 description 1
- 244000000231 Sesamum indicum Species 0.000 description 1
- 235000003434 Sesamum indicum Nutrition 0.000 description 1
- 244000044822 Simmondsia californica Species 0.000 description 1
- 235000004433 Simmondsia californica Nutrition 0.000 description 1
- 244000061457 Solanum nigrum Species 0.000 description 1
- 229910010413 TiO 2 Inorganic materials 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 239000006096 absorbing agent Substances 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- XNEFYCZVKIDDMS-UHFFFAOYSA-N avobenzone Chemical compound C1=CC(OC)=CC=C1C(=O)CC(=O)C1=CC=C(C(C)(C)C)C=C1 XNEFYCZVKIDDMS-UHFFFAOYSA-N 0.000 description 1
- 229960005193 avobenzone Drugs 0.000 description 1
- 208000003373 basosquamous carcinoma Diseases 0.000 description 1
- 208000002352 blister Diseases 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- PBAYDYUZOSNJGU-UHFFFAOYSA-N chelidonic acid Natural products OC(=O)C1=CC(=O)C=C(C(O)=O)O1 PBAYDYUZOSNJGU-UHFFFAOYSA-N 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 125000000753 cycloalkyl group Chemical group 0.000 description 1
- 229940086555 cyclomethicone Drugs 0.000 description 1
- 229960003949 dexpanthenol Drugs 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 229940008099 dimethicone Drugs 0.000 description 1
- 239000004205 dimethyl polysiloxane Substances 0.000 description 1
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 210000000245 forearm Anatomy 0.000 description 1
- 239000004519 grease Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 239000008240 homogeneous mixture Substances 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- XUGNVMKQXJXZCD-UHFFFAOYSA-N isopropyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC(C)C XUGNVMKQXJXZCD-UHFFFAOYSA-N 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 229940042472 mineral oil Drugs 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- 231100000344 non-irritating Toxicity 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- FMJSMJQBSVNSBF-UHFFFAOYSA-N octocrylene Chemical group C=1C=CC=CC=1C(=C(C#N)C(=O)OCC(CC)CCCC)C1=CC=CC=C1 FMJSMJQBSVNSBF-UHFFFAOYSA-N 0.000 description 1
- 229960000601 octocrylene Drugs 0.000 description 1
- 230000037312 oily skin Effects 0.000 description 1
- DXGLGDHPHMLXJC-UHFFFAOYSA-N oxybenzone Chemical compound OC1=CC(OC)=CC=C1C(=O)C1=CC=CC=C1 DXGLGDHPHMLXJC-UHFFFAOYSA-N 0.000 description 1
- 229960001173 oxybenzone Drugs 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 230000008447 perception Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000008845 photoaging Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 239000011164 primary particle Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 239000005871 repellent Substances 0.000 description 1
- 210000001732 sebaceous gland Anatomy 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 230000008833 sun damage Effects 0.000 description 1
- 230000037072 sun protection Effects 0.000 description 1
- 230000009182 swimming Effects 0.000 description 1
- 239000004753 textile Substances 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/31—Hydrocarbons
- A61K8/315—Halogenated hydrocarbons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
- A61K8/27—Zinc; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
- A61K8/29—Titanium; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
- A61K8/347—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/42—Amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/671—Vitamin A; Derivatives thereof, e.g. ester of vitamin A acid, ester of retinol, retinol, retinal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/678—Tocopherol, i.e. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/69—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing fluorine
- A61K8/70—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing fluorine containing perfluoro groups, e.g. perfluoroethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/92—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof
- A61K8/922—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof of vegetable origin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
- A61Q17/04—Topical preparations for affording protection against sunlight or other radiation; Topical sun tanning preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/004—Aftersun preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/48—Thickener, Thickening system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/87—Application Devices; Containers; Packaging
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- Chemical & Material Sciences (AREA)
- Inorganic Chemistry (AREA)
- Dermatology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Emergency Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cosmetics (AREA)
Description
1.
日焼け止め製剤であって、
半フッ素化アルカン、
二酸化チタン、酸化亜鉛、およびそれらの混合物から選択される1~6重量%の金属酸化物、
固形増粘剤、ならびに
任意選択で、共溶媒および/または油成分および/または有効成分
を含む、日焼け止め製剤。
2.
半フッ素化アルカンが、式F(CF2)n(CH2)mHであり、式中、nが4~6の整数であり、mが5~10の整数である、先行する項目のいずれかの日焼け止め製剤。
3.
半フッ素化アルカンが、1-パーフルオロヘキシル-オクタン(F6H8)、1-パーフルオロブチル-ペンタン(F4H5)、1-パーフルオロヘキシルーデカン(F6H10)、1-パーフルオロブチル-オクタン(F4H8)、1-パーフルオロブチル-デカン(F4H10)、およびそれらの組み合わせから選択される、先行する項目のいずれかの日焼け止め製剤。
4.
半フッ素化アルカンが、1-パーフルオロヘキシル-オクタン(F6H8)である、先行する項目のいずれかの日焼け止め製剤。
5.
製剤が、50~95重量%の半フッ素化アルカンを含む、先行する項目のいずれかの日焼け止め製剤。
6.
製剤が、製剤の総重量に基づいて、80~84重量%の半フッ素化アルカン、約4~6重量%の金属酸化物、3~8重量%の固体増粘剤、好ましくは80~84重量%の1-パーフルオロヘキシルオクタン、4~6重量%の金属酸化物、および3~8重量%の固体増粘剤を含む、先行する項目のいずれかの日焼け止め製剤。
7.
製剤が、80~84重量%の半フッ素化アルカン、約4~6重量%の二酸化チタン、3~8重量%の固体増粘剤を含む、先行する項目のいずれかの日焼け止め製剤。
8.
金属酸化物粒子が、1~100nmの平均粒径を有する、先行する項目のいずれかの日焼け止め製剤。
9.
固体増粘剤が、天然または合成の増粘剤である、先行する項目のいずれかの日焼け止め製剤。
10.
製剤が、製剤の総重量に基づいて、少なくとも1重量%、好ましくは少なくとも3重量%、より好ましくは少なくとも5重量%の固体増粘剤を含む、先行する項目のいずれかの日焼け止め製剤。
11.
製剤が、製剤の総重量に基づいて、多くても40重量%、好ましくは多くても30重量%、より好ましくは多くても20重量%、最も好ましくは多くても10重量%の固体増粘剤を含む、先行する項目のいずれかの日焼け止め製剤。
12.
天然または合成の増粘剤が、植物ワックス、動物ワックス、石油由来ワックス、トリグリセリド、セチルアルコール、テトラデカノール、またはそれらの組み合わせから選択される、先行する項目のいずれかの日焼け止め製剤。
13.
増粘剤が、蜜蝋、ラノリン(ウールワックス)、カルナウバワックス、カンデリラワックス、ヒマシワックス、ライスブランワックス(ライスワックス)、スペルマセチワックス、ホホバオイル、ブランワックス、モンタンワックス、カポックワックス、ベイベリーワックス、シェラックワックス、サトウキビワックス、パラフィンワックス、セレシンワックスからなる群から選択されるワックスである、先行する項目のいずれかの日焼け止め製剤。
14.
製剤中の共溶媒、油成分、および有効成分の総量が、最大約45重量%、好ましくは最大約20重量%、より好ましくは最大約10重量%である、先行する項目のいずれかの日焼け止め製剤。
15.
軟膏の形態である、先行する項目のいずれかの日焼け止め製剤。
16.
日焼け止め製剤が、少なくとも6の太陽光線保護指数を有する、先行する項目のいずれかの日焼け止め製剤。
17.
製剤が水を含まない、先行する項目のいずれかの日焼け止め製剤。
18.
製剤が、防腐剤を含まない、先行する項目のいずれかの日焼け止め製剤。
19.
パンテノール、チモール、ティーツリーオイル、パルミチン酸レチノール、トコフェロールから選択される有効成分を含む、前述の項目のいずれかの日焼け止め製剤。
20.
日焼けから皮膚を保護するための項目1~19のいずれかに記載の日焼け止め製剤の使用。
21.
医薬品として使用するための、項目1~19のいずれかに記載の組成物。
22.
UV線によって引き起こされる皮膚細胞損傷の予防に使用するための、項目1~19のいずれかに記載の組成物。
23.
皮膚がんの予防に使用するための、項目1~19のいずれかに記載の組成物。
24.
項目1~19に記載されるような日焼け止め製剤を対象の皮膚に局所投与することを含む、UV線によって引き起こされる結果および/または損傷から皮膚を保護および/または予防する方法。
25.
皮膚を日焼けから保護するのに有効である、項目24の方法。
26.
UV線によって引き起こされる皮膚細胞の損傷を予防するのに有効である、項目24の方法。
27.
皮膚がんの発症を予防するのに有効である、項目24~26の方法。
28.
項目1~19。のいずれかに記載されるような日焼け止め製剤および日焼け止め製剤を保持するための容器を備えるキット。
29.
先行する項目のいずれかに従って日焼け止め製剤を製造するためのプロセス。
30.
a)すべての成分を混合するステップ、
b)約80℃まで加熱するステップ、
c)室温で冷却するステップ
を含む項目29のプロセス。
日焼け止め製剤
各製剤の成分を好適な容器で秤量した。
投与
実施例1の製剤(SC-1~SC-5)は、非常に快適な半固体製剤として提示される。前腕の皮膚に投与すると、絹のような感触が認められ、製剤は、皮膚に非常に素早く吸収された。投与直後は、まだ白色が観察されたが、穏やかなマッサージ後、30~60秒以内にこの色は、完全に消失し、これは、金属酸化物を含む製剤が角質層に容易に浸透し、皮膚の表面上に着色金属酸化物の痕跡すら残らなかったことを実証した。さらに、日焼け止め製剤は、皮膚に完全に吸収された後、いかなる不快な脂っこい感じも後に残さなかった。日焼け止め剤の皮膚が織物/衣類に接触しても、変色または脂っこいスポットにはならなかった。
Claims (19)
- 日焼け止め製剤であって、
a)半フッ素化アルカン、
b)二酸化チタン、酸化亜鉛、およびそれらの混合物から選択される金属酸化物
を含む、日焼け止め製剤。 - 前記製剤が、固体増粘剤を含む、請求項1に記載の日焼け止め製剤。
- 前記金属酸化物が、前記製剤の総重量に基づいて、1~6重量パーセントの濃度で存在する、請求項1~2のいずれかに記載の日焼け止め製剤。
- 前記半フッ素化アルカンが、式F(CF2)n(CH2)mHであり、式中、nが4~6から選択される整数であり、mが5~10から選択される整数である、請求項1~3のいずれかに記載の日焼け止め製剤。
- 前記半フッ素化アルカンが、1-パーフルオロヘキシル-オクタン(F6H8)、1-パーフルオロブチル-ペンタン(F4H5)、1-パーフルオロヘキシル-デカン(F6H10)、1-パーフルオロブチル-オクタン(F4H8)、1-パーフルオロブチル-デカン(F4H10)、およびそれらの組み合わせから選択される、請求項1~4のいずれかに記載の日焼け止め製剤。
- 前記製剤が、前記製剤の総重量に基づいて、50~95重量%の半フッ素化アルカンを含む、請求項1~5のいずれかに記載の日焼け止め製剤。
- 前記金属酸化物粒子が、1~100nmの平均粒径を有する、請求項1~6のいずれかに記載の日焼け止め製剤。
- 前記製剤が、前記製剤の総重量に基づいて、1~40重量%の固体増粘剤を含む、請求項2に記載の日焼け止め製剤。
- 前記固体増粘剤が、植物ワックス、動物ワックス、石油由来ワックス、トリグリセリド、セチルアルコール、テトラデカノール、またはそれらの組み合わせから選択される天然または合成の増粘剤である、請求項2または8に記載の日焼け止め製剤。
- ワックスが、蜜蝋、ラノリン(ウールワックス)、カルナウバワックス、カンデリラワックス、ヒマシワックス、ライスブランワックス(ライスワックス)、スペルマセチワックス、ホホバオイル、ブランワックス、モンタンワックス、カポックワックス、ベイベリーワックス、シェラックワックス、サトウキビワックス、パラフィンワックス、セレシンワックスからなる群から選択される、請求項9に記載の日焼け止め製剤。
- 軟膏の形態である、請求項1~10のいずれかに記載の日焼け止め製剤。
- 前記製剤が、水を含まないかつ/または防腐剤を含まない、請求項1~11のいずれかに記載の日焼け止め製剤。
- パンテノール、チモール、ティーツリーオイル、パルミチン酸レチノール、又はトコフェロールを含む、請求項1~12のいずれかに記載の日焼け止め製剤。
- イソプロパノール、エタノール、液体中鎖トリグリセリド、N-メチル-2-ピロリドン、ジエチレングリコールモノメチルエーテル、ジエチレングリコールモノエチルエーテル、酢酸エチル、オレイン酸エチル、オクチルドデカノール、セバシン酸ジエチルから選択される共溶媒を含む、請求項1~13のいずれかに記載の日焼け止め製剤。
- スクアラン、スクアレン、エッセンシャルオイル、液体トリグリセリド、シリコーンオイル、ミネラルオイル、皮膚軟化植物油から選択される油性材料を含む、請求項1~14のいずれかに記載の日焼け止め製剤。
- UV線によって引き起こされる皮膚細胞の損傷を予防する方法で使用するための、請求項1~15のいずれかに記載の日焼け止め製剤。
- 皮膚がんの予防方法に使用するための、請求項1~15のいずれかに記載の日焼け止め製剤。
- 皮膚を日焼けから保護するための、請求項1~15のいずれかに記載の日焼け止め製剤の使用。
- 請求項1~15のいずれかに記載の日焼け止め製剤および請求項1~15のいずれかに記載の日焼け止め製剤を保持するための容器を備える、キット。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP18197171 | 2018-09-27 | ||
EP18197171.4 | 2018-09-27 | ||
PCT/EP2019/075358 WO2020064556A1 (en) | 2018-09-27 | 2019-09-20 | Topical sunscreen formulation |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2022501343A JP2022501343A (ja) | 2022-01-06 |
JPWO2020064556A5 JPWO2020064556A5 (ja) | 2022-09-28 |
JP7292567B2 true JP7292567B2 (ja) | 2023-06-19 |
Family
ID=63685867
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2021514553A Active JP7292567B2 (ja) | 2018-09-27 | 2019-09-20 | 局所日焼け止め製剤 |
Country Status (10)
Country | Link |
---|---|
US (1) | US11510855B2 (ja) |
EP (1) | EP3856128B1 (ja) |
JP (1) | JP7292567B2 (ja) |
KR (1) | KR102404412B1 (ja) |
CN (1) | CN112739311B (ja) |
AU (1) | AU2019345929B2 (ja) |
CA (1) | CA3111870C (ja) |
ES (1) | ES2950878T3 (ja) |
PL (1) | PL3856128T3 (ja) |
WO (1) | WO2020064556A1 (ja) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT3192501T (pt) | 2011-05-25 | 2020-07-31 | Novaliq Gmbh | Composição farmacêutica tópica à base de alcanos semifluorados |
EP3856124A1 (en) | 2018-09-27 | 2021-08-04 | Novaliq GmbH | Lipid barrier repair |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6262126B1 (en) | 1995-09-29 | 2001-07-17 | Hasso Meinert | Semi-fluorinated alkanes and their use |
EP3311802A1 (en) | 2011-05-25 | 2018-04-25 | Novaliq GmbH | Topical pharmaceutical composition based on semifluorinated alkanes |
Family Cites Families (72)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2616927A (en) | 1950-05-12 | 1952-11-04 | Minnesota Mining & Mfg | Fluorocarbon tertiary amines |
JPS5721312A (en) | 1980-07-12 | 1982-02-04 | Green Cross Corp:The | Breathable ointment |
US5077036A (en) | 1986-01-14 | 1991-12-31 | Alliance Pharmaceutical Corp. | Biocompatible stable fluorocarbon emulsions for contrast enhancement and oxygen transport comprising 40-125% wt./volume fluorocarbon combined with a phospholipid |
JPH0764702B2 (ja) * | 1986-04-23 | 1995-07-12 | 鐘紡株式会社 | 多相乳化型化粧料 |
JPH03279323A (ja) * | 1989-12-15 | 1991-12-10 | Johnson & Johnson Consumer Prod Inc | 日焼け止め組成物 |
JP3046346B2 (ja) | 1990-03-12 | 2000-05-29 | 昭和電工株式会社 | 外用剤基剤又は補助剤とそれを含有する人又は動物の外用剤 |
US5518731A (en) | 1990-09-27 | 1996-05-21 | Allergan, Inc. | Nonaqueous fluorinated drug delivery vehicle suspensions |
US5152997A (en) | 1990-12-11 | 1992-10-06 | Theratech, Inc. | Method and device for transdermally administering testosterone across nonscrotal skin at therapeutically effective levels |
US5326566A (en) | 1991-05-17 | 1994-07-05 | Bristol-Myers Squibb Company | Use of dibutyl adipate and isopropyl myristate in topical and transdermal products |
FR2679150A1 (fr) | 1991-07-17 | 1993-01-22 | Atta | Preparations comprenant un fluorocarbure ou compose hautement fluore et un compose organique lipophile-fluorophile, et leurs utilisations. |
DE4405627A1 (de) * | 1994-02-22 | 1995-08-24 | Hoechst Ag | Fluorkohlenwasserstoffe enthaltende Ölemulsionen |
FR2720943B1 (fr) | 1994-06-09 | 1996-08-23 | Applic Transferts Technolo | Emulsions inverses stables à forte concentration en composé(s) fluoré(s) et leur utilisation pour l'administration pulmonaire de médicaments et pour la fabrication d'émulsions multiples. |
US5696164A (en) | 1994-12-22 | 1997-12-09 | Johnson & Johnson Consumer Products, Inc. | Antifungal treatment of nails |
US5874481A (en) | 1995-06-07 | 1999-02-23 | Alliance Pharmaceutical Corp. | Fluorochemical solutions for the delivery of lipophilic pharmaceutical agents |
US5667809A (en) | 1995-06-07 | 1997-09-16 | Alliance Pharmaceutical Corp. | Continuous fluorochemical microdispersions for the delivery of lipophilic pharmaceutical agents |
US5874469A (en) | 1996-01-05 | 1999-02-23 | Alcon Laboratories, Inc. | Fluoroalkyl hydrocarbons for administering water insoluble or unstable drugs |
RU2111738C1 (ru) | 1996-06-24 | 1998-05-27 | Акционерное общество "НИЗАР" | Средство для усиления солнцезащитной активности фотозащитных агентов |
FR2752161B1 (fr) | 1996-08-07 | 1998-09-25 | Atta | Emulsions multiples de type hydrocarbure-dans-eau-dans- fluorocarbone pour le transport de substances medicamenteuses hydrophiles et/ou lipophiles |
US5863560A (en) | 1996-09-11 | 1999-01-26 | Virotex Corporation | Compositions and methods for topical application of therapeutic agents |
US5980936A (en) | 1997-08-07 | 1999-11-09 | Alliance Pharmaceutical Corp. | Multiple emulsions comprising a hydrophobic continuous phase |
PT983037E (pt) | 1998-02-09 | 2003-09-30 | Macrochem Corp | Verniz para unhas antifungico |
US6159977A (en) | 1998-11-16 | 2000-12-12 | Astan, Inc. | Therapeutic anti-fungal nail preparation |
PT1666026E (pt) | 1999-02-08 | 2012-03-15 | Intarcia Therapeutics Inc | Veículos viscosos não aquosos biocompatíveis monofásicos e métodos para a preparação dos mesmos |
FR2795638B1 (fr) * | 1999-07-02 | 2003-05-09 | Oreal | Compositions cosmetiques photoprotectrices et utilisations |
US6528086B2 (en) | 1999-09-28 | 2003-03-04 | Zars, Inc. | Methods and apparatus for drug delivery involving phase changing formulations |
US20060204458A1 (en) * | 2000-10-26 | 2006-09-14 | Holloway William D Jr | Anti-aging methods and composition |
DE10024413A1 (de) | 2000-05-19 | 2001-12-06 | Mika Pharma Gmbh | Pharmazeutische und/oder kosmetische Zubereitung |
DE10042412B4 (de) | 2000-08-30 | 2005-12-22 | Lts Lohmann Therapie-Systeme Ag | Transdermales therapeutisches System zur Abgabe von Venlafaxin, und seine Verwendung |
WO2002089849A1 (en) | 2001-05-07 | 2002-11-14 | Corium International | Compositions and delivery systems for administration of a local anesthetic agent |
US6936241B2 (en) * | 2001-08-17 | 2005-08-30 | The Procter & Gamble Company | Sunscreen composition |
WO2003020250A1 (en) | 2001-09-04 | 2003-03-13 | Trommsdorff Gmbh & Co. Kg Arzneimittel | Plaster for the treatment of dysfunctions and disorders of nail growth |
AU2003206183A1 (en) | 2002-01-26 | 2003-09-02 | Micro Science Tech Co., Ltd | Composition containing moutan root bark extract as active ingredient |
MXPA06002163A (es) | 2003-08-25 | 2006-05-22 | Foamix Ltd | Espuma farmaceutica de penetracion. |
US20050079210A1 (en) | 2003-10-09 | 2005-04-14 | Gupta Shyam K. | Liposomal delivery system for topical pharmaceutical, cosmeceutical, and cosmetic ingredients |
ES2377932T3 (es) | 2003-10-10 | 2012-04-03 | Ferring Bv | Formulación farmacéutica transdérmica para minimizar los residuos sobre la piel |
WO2005051305A2 (en) | 2003-11-19 | 2005-06-09 | Barnes-Jewish Hospital | Enhanced drug delivery |
DE10358306B8 (de) * | 2003-12-08 | 2005-03-03 | Coty B.V. | Kosmetisches und dermatologisches Sauerstoff-Trägersystem, Verfahren zu dessen Herstellung sowie seine Verwendung |
GB0408164D0 (en) | 2004-04-13 | 2004-05-19 | Immune Targeting Systems Ltd | Antigen delivery vectors and constructs |
ES2387619T3 (es) | 2004-04-19 | 2012-09-27 | Centre National De La Recherche Scientifique (Cnrs) | Suplementos de tensioactivos pulmonares |
US20060078580A1 (en) | 2004-10-08 | 2006-04-13 | Mediquest Therapeutics, Inc. | Organo-gel formulations for therapeutic applications |
US7740875B2 (en) | 2004-10-08 | 2010-06-22 | Mediquest Therapeutics, Inc. | Organo-gel formulations for therapeutic applications |
EP1688161A1 (en) | 2004-11-02 | 2006-08-09 | Switch Biotech Aktiengesellschaft | Use of pirlindole for the treatment of diseases which are characterized by proliferation of t-lymphocytes and/or hyperproliferation of keratinocytes in particular atopic dermatitis and psoriasis |
GB0511499D0 (en) | 2005-06-06 | 2005-07-13 | Medpharm Ltd | Topical ungual formulations |
FR2892023B1 (fr) | 2005-10-14 | 2009-09-25 | Galderma Sa | Composition pharmaceutique a base d'amorolfine et d'agent filmogene hydrosoluble pour application ungueale et peri-ungueale |
DE102005050431A1 (de) | 2005-10-21 | 2007-04-26 | Lts Lohmann Therapie-Systeme Ag | Transdermales therapeutisches System zur Verabreicherung lipophiler und/oder wenig hautpermeabler Wirkstoffe |
DE102005055811A1 (de) | 2005-11-23 | 2007-05-31 | Novaliq Gmbh | Verwendung einer Zusammensetzung zur Konservierung von Organen und Gliedmaßen |
TWI376239B (en) | 2006-02-01 | 2012-11-11 | Andrew Xian Chen | Vitamin e succinate stabilized pharmaceutical compositions, methods for the preparation and the use thereof |
DK2207529T3 (en) * | 2007-09-07 | 2015-03-09 | Mati Therapeutics Inc | PHARMACEUTICAL cores for the sustained release of therapeutic agents |
DK2110126T3 (da) | 2008-04-18 | 2012-02-27 | Novaliq Gmbh | Inhalations- og instillationsanvendelse af semifluorerede alkaner som aktiv bestanddel-bærere inden for det intrapulmonale område |
BRPI1006790B8 (pt) | 2009-07-24 | 2021-05-25 | Mika Pharma Ges Fuer Die Entwicklung Und Vermarktung Pharmazeutischer Produkte Mbh | método para desenvolver uma composição farmacêutica líquida a ser aplicada na pele como uma espuma e composição adequada para uso tópico |
HUP1000362A2 (en) | 2010-07-12 | 2012-11-28 | Egis Gyogyszergyar Nyrt | Antiseptic and disinfecting compositions having reduced iodine content |
EP2444063A1 (en) | 2010-10-20 | 2012-04-25 | Novaliq GmbH | Liquid pharmaceutical compositions for the delivery of active ingredients |
US20120100183A1 (en) | 2010-10-23 | 2012-04-26 | Joel Schlessinger | Topical base and active agent-containing compositions, and methods for improving and treating skin |
TR201901309T4 (tr) | 2011-01-04 | 2019-02-21 | Novaliq Gmbh | Semiflorlanmış alkanları içeren o/w emülsiyonları. |
US20120219640A1 (en) | 2011-02-25 | 2012-08-30 | Wright Kenneth W | Anti-infective solution for athlete's foot |
WO2012160180A2 (en) | 2011-05-25 | 2012-11-29 | Novaliq Gmbh | Pharmaceutical composition for administration to nails |
US8758826B2 (en) | 2011-07-05 | 2014-06-24 | Wet Inc. | Cannabinoid receptor binding agents, compositions, and methods |
BR112014017719A8 (pt) | 2012-01-23 | 2017-07-11 | Novaliq Gmbh | Composições de proteína estabilizada baseadas em alcanos semifluorados |
PL3181119T3 (pl) | 2012-09-12 | 2020-01-31 | Novaliq Gmbh | Kompozycje semifluorowanych alkanów do zastosowania w leczeniu suchego zapalenia spojówki i rogówki |
CN113679698B (zh) | 2012-09-12 | 2022-07-26 | 诺瓦利克有限责任公司 | 包含半氟化烷烃的混合物的组合物 |
EP2783703A1 (en) | 2013-03-25 | 2014-10-01 | B. Braun Melsungen AG | Semifluorocarbon compound containing contrast agent |
AU2014295052B2 (en) | 2013-07-23 | 2018-08-30 | Novaliq Gmbh | Stabilized antibody compositions |
FR3013977A1 (fr) * | 2013-12-03 | 2015-06-05 | Oreal | Composition cosmetique comprenant des filtres uv |
EP2944324A1 (de) * | 2014-05-13 | 2015-11-18 | LTS LOHMANN Therapie-Systeme AG | Verwendung von semifluorierten Alkanen in transdermalen therapeutischen Systemen |
US9186305B1 (en) | 2014-05-19 | 2015-11-17 | Shiseido Company, Ltd. | Sunscreen products in which excessive whiteness due to titanium dioxide and zinc oxide is visually masked upon skin application |
ES2803248T3 (es) | 2015-09-30 | 2021-01-25 | Novaliq Gmbh | 2-perfluorohexil octano para administración oftálmica |
CN111743882A (zh) | 2015-09-30 | 2020-10-09 | 诺瓦利克有限责任公司 | 半氟化化合物和其组合物 |
CA2983765C (en) | 2016-06-08 | 2018-02-27 | Majda Ficko | Sun block formulation |
ES2763121T3 (es) | 2016-06-23 | 2020-05-27 | Novaliq Gmbh | Método de administración tópica |
CN106176937A (zh) | 2016-08-24 | 2016-12-07 | 刘艺鹏 | 湿疹、痤疮软膏 |
CN110678207B (zh) | 2017-04-21 | 2024-08-02 | 德马利克治疗公司 | 碘组合物 |
EP3856124A1 (en) | 2018-09-27 | 2021-08-04 | Novaliq GmbH | Lipid barrier repair |
-
2019
- 2019-09-20 PL PL19769532.3T patent/PL3856128T3/pl unknown
- 2019-09-20 AU AU2019345929A patent/AU2019345929B2/en active Active
- 2019-09-20 WO PCT/EP2019/075358 patent/WO2020064556A1/en unknown
- 2019-09-20 ES ES19769532T patent/ES2950878T3/es active Active
- 2019-09-20 EP EP19769532.3A patent/EP3856128B1/en active Active
- 2019-09-20 CA CA3111870A patent/CA3111870C/en active Active
- 2019-09-20 US US17/280,055 patent/US11510855B2/en active Active
- 2019-09-20 CN CN201980062465.0A patent/CN112739311B/zh active Active
- 2019-09-20 KR KR1020217012447A patent/KR102404412B1/ko active IP Right Grant
- 2019-09-20 JP JP2021514553A patent/JP7292567B2/ja active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6262126B1 (en) | 1995-09-29 | 2001-07-17 | Hasso Meinert | Semi-fluorinated alkanes and their use |
EP3311802A1 (en) | 2011-05-25 | 2018-04-25 | Novaliq GmbH | Topical pharmaceutical composition based on semifluorinated alkanes |
Also Published As
Publication number | Publication date |
---|---|
EP3856128A1 (en) | 2021-08-04 |
JP2022501343A (ja) | 2022-01-06 |
PL3856128T3 (pl) | 2023-10-16 |
KR20210068491A (ko) | 2021-06-09 |
CA3111870A1 (en) | 2020-04-02 |
AU2019345929B2 (en) | 2022-02-03 |
EP3856128C0 (en) | 2023-06-07 |
US11510855B2 (en) | 2022-11-29 |
CN112739311B (zh) | 2023-07-14 |
AU2019345929A1 (en) | 2021-05-13 |
CA3111870C (en) | 2022-04-12 |
KR102404412B1 (ko) | 2022-05-31 |
WO2020064556A1 (en) | 2020-04-02 |
EP3856128B1 (en) | 2023-06-07 |
CN112739311A (zh) | 2021-04-30 |
ES2950878T3 (es) | 2023-10-16 |
US20210308024A1 (en) | 2021-10-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2885808B2 (ja) | ソルビン酸トコフェロールと抗炎症剤を含む光保護組成物 | |
JP2812690B2 (ja) | ソルビン酸トコフェロールを含有する光保護組成物 | |
US20080233060A1 (en) | High SPF transparent or translucent, cytoprotective, biodegradable, UV radiation resistant compositions | |
EP2425810B1 (en) | Sunscreen compositions | |
JPH0710750A (ja) | δ−アミノリヴリン酸含有化粧用または皮膚科学用調合物 | |
AU2003237369A1 (en) | Sunscreen compositions | |
JP2001072531A (ja) | 化粧品配合物またはスキンケア用配合物の耐水性を改善する添加物 | |
JPS636526B2 (ja) | ||
EP0904051A1 (de) | Kosmetische oder pharmazeutische zubereitungen mit vermindertem klebrigkeitsgefühl | |
US7615231B2 (en) | Methods for enhancing the morphology, tone, texture and/or appearance of skin or hair using a meadowlactone | |
JP7292567B2 (ja) | 局所日焼け止め製剤 | |
JPS63146810A (ja) | 光に安定な化粧品組成物 | |
US3479428A (en) | Sunscreen composition and method of using the same | |
JP2017197434A (ja) | 水中油型日焼け止め化粧料 | |
HU218591B (hu) | Szinergetikus hatású, fényszűrő keveréket tartalmazó, napvédő kozmetikai készítmény és alkalmazása | |
EP3346982B1 (en) | Mixtures of pelargonic acid esters. | |
DE10032165A1 (de) | Verwendung von physiologisch verträglichen Sulfinsäuren als Antioxidans oder Radikalfänger in kosmetischen oder dermatologischen Zubereitungen | |
JP6445981B2 (ja) | 脂肪酸および非イオン性直鎖ポリマーを含む日焼け止め剤組成物 | |
DE19739349A1 (de) | Verwendung von Troxerutin als Antioxidans oder Radikalfänger in kosmetischen oder dermatologischen Zubereitungen | |
JPH08208419A (ja) | 化粧用組成物中の酸化防止剤としてクロロゲン酸の使用およびクロロゲン酸を含んで成る組成物 | |
JPH08245362A (ja) | 紫外線損傷防御用外用剤 | |
KR20170143097A (ko) | 피토스핑고신 유도체를 포함하는 기능성 화장료 조성물 | |
DE19941595A1 (de) | Verwendung von anellierten Benzolderivaten als Antioxidans oder Radikalfänger in kosmetischen Zubereitungen | |
JP2024124275A (ja) | アルコール性組成物 | |
DE19739044A1 (de) | Verwendung von Dihydrorobinetin als Antioxidans oder Radikalfänger in kosmetischen oder dermatologischen Zubereitungen |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220916 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20220916 |
|
A871 | Explanation of circumstances concerning accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A871 Effective date: 20220916 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20221108 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230203 |
|
TRDD | Decision of grant or rejection written | ||
A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20230327 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20230329 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20230328 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20230426 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230509 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 7292567 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |